Cancer Vaccines Represent The Next Frontier For Oncology And Personalized Medicine

Strong results from a phase 2 trial pairing an experimental mRNA-based therapeutic cancer vaccine (mRNA-4157) with a monoclonal antibody drug to treat adjuvant melanoma represents a potential inflection point for oncology. Assuming mRNA-4157 shows similar safety and efficacy in a confirmatory trial before earning FDA approval, this news will have significant implications for biopharma research and development, drug manufacturing and, of course, patients.

However, many key questions—and barriers to adoption—remain. Learn about the implications of this recent announcement, the most pressing barriers to adoption and scale, recommendations for biopharmas moving forward, and the future of cancer treatment.